

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX becomes ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Singular Health Group Limited
ABN	58 639 242 765

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of director	Denning Chong
Date of last notice	30 July 2024

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder)	<p>(1) JCC HEALTH PTY LTD <THE JDE MEDVR A/C> - An entity controlled by Mr Chong, and of which he is a beneficiary</p> <p>(2) JDE CAPITAL PTY LTD <JDE CAPITAL A/C> - An entity controlled by Mr Chong, and of which he is a beneficiary</p>
Date of change	09 January 2025

⁺ See [chapter 19](#) for defined terms.

No. of securities held prior to change	<p>(1.1) 4,640,869 - ORDINARY FULLY PAID SHARES</p> <p>(1.2) 4,500,000 - UNLISTED OPTIONS @ \$0.30 EXP 10/02/2025</p> <p>(1.3) 1,250,000 - UNLISTED OPTIONS @ \$0.08 EXP 08/12/2027</p> <p>(1.4) 1,200,000 - PERFORMANCE RIGHTS - CLASS B</p> <p>(1.5) 5,000,000 - PERFORMANCE RIGHTS EXP 30/06/2028</p> <p>(2.1) 4,667,706 - ORDINARY FULLY PAID SHARES</p> <p>(2.2) 1,818,182 - UNLISTED OPTIONS @ \$0.10 EXP 26/06/2026</p> <p>(2.3) 10,000,000 - UNLISTED OPTIONS @ \$0.08 EXP 08/12/2027</p> <p>(2.4) 1,000,000 - PERFORMANCE RIGHTS - TRANCHE A</p> <p>(2.5) 500,000 - PERFORMANCE RIGHTS - TRANCHE B</p> <p>(2.6) 4,500,000 - PERFORMANCE RIGHTS EXP 8/12/2027</p> <p>(2.7) 5,000,000 - PERFORMANCE RIGHTS EXP 30/06/2028</p>
Class	PERFORMANCE RIGHTS - CLASS B
Number acquired	NIL
Number disposed	1,200,000 - PERFORMANCE RIGHTS - CLASS B
Value/Consideration	NIL

⁺ See [chapter 19](#) for defined terms.

No. of securities held after change	(1.1) 4,640,869 - ORDINARY FULLY PAID SHARES (1.2) 4,500,000 - UNLISTED OPTIONS @ \$0.30 EXP 10/02/2025 (1.3) 1,250,000 - UNLISTED OPTIONS @ \$0.08 EXP 08/12/2027 (1.4) 5,000,000 - PERFORMANCE RIGHTS EXP 30/06/2028 (2.1) 4,667,706 - ORDINARY FULLY PAID SHARES (2.2) 1,818,182 - UNLISTED OPTIONS @ \$0.10 EXP 26/06/2026 (2.3) 10,000,000 - UNLISTED OPTIONS @ \$0.08 EXP 08/12/2027 (2.4) 1,000,000 - PERFORMANCE RIGHTS - TRANCHE A (2.5) 500,000 - PERFORMANCE RIGHTS - TRANCHE B (2.6) 4,500,000 - PERFORMANCE RIGHTS EXP 8/12/2027 (2.7) 5,000,000 - PERFORMANCE RIGHTS EXP 30/06/2028
Nature of change	Lapse of unvested performance rights

Part 2 - Change of director's relevant interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration	N/A
Interest after change	N/A

Part 3 - ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A

⁺ See [chapter 19](#) for defined terms.

If prior written clearance was provided, on what date was this provided?	N/A
--	-----